Note: [*] Visiting Scientist from Chiba University School of Medicine, First Department of Surgery, Chiba, Japan.
Note: [**] Palmer Institute of Graduate Studies & Research, Palmer College, 741 Bradt St., Davenport, IA 52803, USA.
Note: [] Address reprint requests to Dr. Mark C. Glassy, Sci-Clone, Inc., 10246 Parkdale Avenue, San Diego, CA 92126, USA.
Abstract: The use of the severe combined immunodeficient mouse (SCID), CB-17/Icr//Imd-SCID, was investigated for the production of human hybridoma ascites containing human antibody. Human-human hybridomas, generated from the fusion of lymphocytes isolated from regional draining lymph nodes of cancer patients with the SHFP-1 fusion partner, were injected i.p. at various cell concentrations into pristane-primed SCID mice. Ascites growth was typically observed at 7–14 days postinoculation. No significant differences in ascites yield or production were observed between IgG- and IgM-secreting hybridomas. Yields of immunoreactive human immunoglobulin ranged from approximately 0.5 to 3 mg/ml of harvested ascites. The ease and relatively low cost suggest that the use of SCID mice is preferred over conventional and costly large-scale industrial procedures.
